drugset / Trial / NCT00148707
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
Phase 2
Completed
45 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect information on what effects (good or bad) CT-2103 (Xyotax) has on breast cancer as well as any side effects the drug may cause.
Timeline
- Start
- 2004-10
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | paclitaxel poliglumex | Other / unclassified | — | Intravenous |